Exploring how m6A mRNA methylation affects aging in pancreatic beta cells and diabetes
Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetes
This study is looking at how a specific chemical change in the genetic material of insulin-producing cells in the pancreas affects their aging and function, especially in people with Type 1 and Type 2 diabetes, to find new ways to help these cells work better and survive longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11245924 on NIH RePORTER |
What this research studies
This research investigates the role of m6A mRNA methylation in the aging of pancreatic beta cells, which are crucial for insulin production. By examining how changes in m6A methylation contribute to the decline in beta cell function associated with aging and diabetes, the study aims to identify potential therapeutic targets. The researchers will utilize advanced techniques to analyze the m6A landscape in beta cells from individuals with Type 1 and Type 2 diabetes. This could lead to new strategies for improving beta cell survival and function in diabetic patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults diagnosed with Type 1 or Type 2 diabetes, particularly those experiencing age-related decline in beta cell function.
Not a fit: Patients without diabetes or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance beta cell function and longevity, potentially improving diabetes management.
How similar studies have performed: Previous research has shown promising results in targeting RNA modifications for therapeutic purposes, indicating potential success for this novel approach.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: F de Jesus, Dario — University of Chicago
- Study coordinator: F de Jesus, Dario
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.